GT
HRTX icon

Glenmede Trust’s Heron Therapeutics HRTX Stock Holding History

Glenmede Trust’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-82,050
Closed -$65.6K – 1530
2026
Q1 		$65.6K Sell
82,050
-139
-0.2% -$161 ﹤0.01% 1411
2025
Q4 		$107K Buy
+82,189
New +$101K ﹤0.01% 1341
2025
Q1 		$125K Buy
56,796
+17,173
+43% +$33.3K ﹤0.01% 1259
2024
Q4 		$60.6K Buy
39,623
+7,720
+24% +$12.5K ﹤0.01% 1324
2024
Q3 		$63.5K Buy
31,903
+10,578
+50% +$25.3K ﹤0.01% 1311
2024
Q2 		$74.6K Buy
21,325
+5,135
+32% +$15.8K ﹤0.01% 1265
2024
Q1 		$44.8K Buy
16,190
+4,317
+36% +$10.9K ﹤0.01% 1273
2023
Q4 		$20.2K Buy
+11,873
New +$13.1K ﹤0.01% 1257

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Glenmede Trust's HRTX Position: Q2 2026 in Review

Glenmede Trust sold out of Heron Therapeutics (HRTX) in Q2 2026, closing a stake of 82,050 shares — an estimated $65.6K sold.

Glenmede Trust first reported a position in HRTX in Q4 2023 and held it in 8 quarters. The position peaked at $125K in Q1 2025. 163 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • Glenmede Trust reported no remaining Heron Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Glenmede Trust sold 82,050 Heron Therapeutics shares in Q2 2026, an estimated $65.6K.
  • Glenmede Trust first reported a position in Heron Therapeutics in Q4 2023 and held it in 8 quarters.
  • Glenmede Trust's Heron Therapeutics position peaked at $125K in Q1 2025.
  • 163 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on Glenmede Trust's 13F filing for Q2 2026, filed 10 Aug 2026.